<DOC>
	<DOCNO>NCT01394913</DOCNO>
	<brief_summary>This study comparison safety efficacy two etanercept regimen ( REUMATOCEPT® versus ENBREL® ) treatment Rheumatoid Arthritis .</brief_summary>
	<brief_title>Comparison Two Etanercept Regimens ( REUMATOCEPT® Versus ENBREL® ) Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>Study design : • Double blind , non-inferiority , prospective parallel-group , intend treat trial . Study design : - Experiment duration : 30 week - 9 visit ( day 0 , 14 , 42 , 70 , 98 , 126 , 154 , 182 , 210 ) - Health Assessment Questionnaire ( HAQ ) evaluation - Disease Activity Score ( DAS28 ) evaluation - Clinical Disease Activity Index ( CDAI ) evaluation - American College Rheumatology criterion ( ACR ) evaluation - Visual Activity Schedule ( VAS ) evaluation - Adverse event evaluation</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Patients must able understand study procedure agree participate give write consent . 2 . Patients clinical diagnosis moderate severe rheumatoid arthritis accord American College Rheumatology ( ACR ) criteria ; 3 . Patients least 6 swollen joint 4 . Patients partial response treatment methotrexate 2 month 1 . Pregnancy Lactation 2 . Patients uncontrolled hypertension 3 . Patients rheumatic disease Sjogren syndrome , systemic lupus erythematosus spondyloarthritis 4 . Nonsteroidal antiinflammatory drug last 4 week 5 . Any pathology past medical condition interfere protocol 6 . Patients immunodeficiency and/or immunosuppressive disease ; 7 . Other condition deem reasonable medical investigator disqualification individual study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>